EMA revised guideline on quality of biosimilars open for comments

June 1, 2012 6:47 AM

The European Medicines Agency (EMA) announced yesterday that, it has released a revised guideline for public consultation describing how pharmaceutical companies should address the quality aspects of biosimilar medicines. 

This guideline will update the previous guidance from 2006 and it explains the requirements for the manufacture and comparability testing for biological medicines claiming to be similar to another medicine already on the market.

The 31 May guidance was adopted by the Agency’s Committee for Medicinal Products for Human Use (CHMP) in May 2012. It is open for consultation until the end of November 2012.

The revised guideline can be accessed from here:

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!